Metraipolis › archive › dc_b2a9def2fd13
Characteristics of patients who developed transient anti-adalimumab antibodies — Europe PMC PMID:40993500
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40993500
- DOI
- 10.1186/s12348-[numero omesso]-7
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T18:58:51.177Z
- SHA-256 of the archived text
67fdd65ebbdfd8c8f0d6c9e81f1b24896a61b0d5c419f0517b60b2654bf5b1d6- Stable URL of this page
https://metraipolis.com/documento/dc_b2a9def2fd13
How to cite
Characteristics of patients who developed transient anti-adalimumab antibodies — Europe PMC PMID:40993500 — Europe PMC (en), https://europepmc.org/article/MED/40993500 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b2a9def2fd13 (Metraipolis archive dc_b2a9def2fd13, sha256 67fdd65ebbdfd8c8f0d6c9e81f1b24896a61b0d5c419f0517b60b2654bf5b1d6)
BibTeX
@misc{dcb2a9def2fd13,
title = {Characteristics of patients who developed transient anti-adalimumab antibodies — Europe PMC PMID:40993500},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40993500},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b2a9def2fd13; sha256 67fdd65ebbdfd8c8f0d6c9e81f1b24896a61b0d5c419f0517b60b2654bf5b1d6},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40993500. Agents can read the archived copy with the MCP tool read_document.